• Quince Therapeutics swung to net income of USD 35.91 million, reflecting a USD 67.81 million intangible asset impairment charge offset by a USD 64.33 million fair-value adjustment for contingent consideration.
• Operating loss narrowed 2% to USD 14.59 million, as research and development expense fell 16% to USD 6.85 million; general and administrative costs dropped 11% to USD 4.27 million.
• Cash and cash equivalents totaled USD 18.2 million as of March 31, 2026, and the company said it expects that balance will not fund operations for the 12 months following the filing.
• Development of eDSP was halted after the Phase 3 NEAT trial missed primary and key secondary endpoints; focus shifted to strategic alternatives including a reverse merger, with LifeSci Capital engaged as exclusive financial advisor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-217098), on May 11, 2026, and is solely responsible for the information contained therein.